Table 2.
HIV characteristics and vaccination status for SARS‐CoV‐2 infections among adults with HIV in the Western Cape, stratified by age group (percentages and counts).
| Cases until end of wave 3 | All cases (including wave 4) | |||
|---|---|---|---|---|
| Characteristic |
Ages 15–39 years n = 9321 |
Ages ≥40 years n = 8799 |
All ages n = 18,120 |
All ages n = 22,057 |
| CD4 count (cells/μl) | ||||
| ≥ 500 | 14.0 (1304) | 11.3 (991) | 12.7 (2295) | 12.6 (2775) |
| 200–499 | 15.7 (1465) | 11.5 (1014) | 13.7 (2479) | 13.5 (2986) |
| 50–199 | 7.0 (648) | 5.8 (511) | 6.4 (1159) | 7.1 (1576) |
| 0–49 | 3.6 (333) | 2.2 (191) | 2.9 (524) | 3.5 (773) |
| Unknown | 59.8 (5571) | 69.2 (6092) | 64.4 (11,663) | 63.2 (13,947) |
| Viral load a (copies/ml) | ||||
| 0–999 | 66.4 (5642) | 77.7 (6196) | 71.9 (11,838) | 69.6 (13,913) |
| ≥ 1000 | 10.8 (915) | 7.3 (585) | 9.1 (1500) | 10.0 (2003) |
| Unknown | 22.8 (1941) | 15.0 (1194) | 19.0 (3135) | 20.4 (4068) |
| ART (years since most recent collection) | ||||
| ≥ 2 | 44.2 (4116) | 46.5 (4092) | 45.3 (8208) | 46.0 (10,146) |
| < 2 | 47.0 (4382) | 44.1 (3883) | 45.6 (8265) | 44.6 (9838) |
| No ART | 8.8 (823) | 9.4 (824) | 9.1 (1647) | 9.4 (2073) |
| HIV evidence (years since first) | ||||
| <1 | 9.0 (838) | 5.9 (519) | 7.5 (1357) | 7.7 (1706) |
| 1–5 | 39.2 (3653) | 22.8 (2002) | 31.2 (5655) | 30.9 (6826) |
| 5–10 | 36.5 (3404) | 33.9 (2986) | 35.3 (6390) | 35.3 (7781) |
| ≥ 10 | 15.3 (1426) | 37.4 (3292) | 26.0 (4718) | 26.0 (5744) |
| Vaccination status b | ||||
| None | 97.9 (9126) | 95.2 (8378) | 96.6 (17,504) | 89.6 (19,761) |
| Early | 0.8 (74) | 2.6 (126) | 1.6 (300) | 1.7 (379) |
| Janssen—one vaccine | 1.2 (111) | 1.1 (98) | 1.2 (209) | 3.7 (819) |
| Pfizer—one vaccine | 0.1 (9) | 0.9 (82) | 0.5 (91) | 1.3 (291) |
| Janssen—two vaccines | 0.0 (0) | 0.0 (0) | 0.0 (0) | 0.6 (137) |
| Pfizer—two vaccines | 0.0 (1) | 0.2 (15) | 0.1 (16) | 3.0 (670) |
Abbreviation: ART, antiretroviral therapy.
a
Among those with evidence of ART at any time.
b
The highest level of protection from among six categories: no vaccine received (“None”); <28 days since a first vaccine dose (“Early”); ≥28 days since a first dose of a vaccine, by type (“one vaccine”); or ≥14 days since a second dose, by type (“two vaccines”).